Gastric pentadecapeptide BPC 157 in cytoprotection to resolve major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome

Professional paper - Editorial

• Author: Predrag Sikirić
• Author: Anita Škrtić
• Author: Slaven Gojković
• Author: Ivan Krezić
• Author: Helena Žižek
• Author: Eva Lovrić
• Author: Sunčana Sikirić
• Author: Mario Knežević
• Author: Sanja Štrbe; MBZ: 319335
• Author: Marija Milavić
• Author: Antonio Kokot
• Author: Alenka Boban Blagaić
• Author: Sven Seiwerth
• Author's institution: University of Zagreb; School of Medicine; (Department of Pharmacology)
• Author's institution: University of Zagreb; School of Medicine; (Department of Pathology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Basic Medical Sciences; Pharmacology
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Pathology

Abstract (english)

The stable gastric pentadecapeptide BPC 157 counteracts various venous occlusion-induced syndromes. Summarized are all these arguments, in the Robert's cytoprotection concept, to substantiate the resolution of different major vessel occlusion disturbances, in particular ischemia-reperfusion injury following the Pringle maneuver and Budd-Chiari syndrome, which was obtained by BPC 157 therapy. Conceptually, there is a new point, namely, endothelium maintenance to epithelium maintenance (the recruitment of collateral blood vessels to compensate for vessel occlusion and reestablish blood flow or bypass the occluded or ruptured vessel). In this paper, we summarize the evidence of the native cytoprotective gastric pentadecapeptide BPC 157, which is stable in the human gastric juice, is a membrane stabilizer and counteracts gut-leaky syndrome. As a particular target, it is distinctive from the standard peptide growth factors, involving particular molecular pathways and controlling VEGF and NO pathways. In the early 1990s, BPC 157 appeared as a late outbreak of the Robert's and Szabo's cytoprotection-organoprotection concept, like the previous theoretical/practical breakthrough in the 1980s and the brain-gut axis and gut-brain axis. As the time went on, with its reported effects, it is likely most useful theory practical implementation and justification. Meantime, several reviews suggest that BPC 157, which does not have a lethal dose, has profound cytoprotective activity, used to be demonstrated in ulcerative colitis and multiple sclerosis trials. Likely, it may bring the theory to practical application, starting with the initial argument, no degradation in human gastric juice for more than 24 h, and thereby, the therapeutic effectiveness (including via a therapeutic per-oral regimen) and pleiotropic beneficial effects.

• Keywords (english): Anti-Ulcer Agents; Budd-Chiari Syndrome; Humans; Peptide Fragments; Proteins; Reperfusion Injury / drug therapy; Reperfusion Injury / prevention & control
• Language: english
• Publication type: Professional paper - Editorial
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: World Journal of Gastroenterology
• Numbering: vol. 28, no. 1, pp. 23-46
• p-ISSN: 1007-9327
• DOI: https://doi.org/10.3748/wjg.v28.i1.23
• URN:NBN: urn:nbn:hr:105:440084
• Publication: 2022-01-07
• Document URL: https://www.wjgnet.com/1007-9327/full/v28/i1/23.htm
• Type of resource: Text
• Access conditions: Open access
• Created on: 2022-11-14 09:17:53